Activation of Serotonin 2C Receptors in Dopamine Neurons Inhibits Binge-like Eating in Mice

Biological Psychiatry

Volumn 81, Issue 9, 2017, Pages 737-747

  Xu, Pingwen ^a   He, Yanlin ^a   Cao, Xuehong ^a   Valencia Torres, Lourdes ^b   Yan, Xiaofeng ^a   Saito, Kenji ^a   Wang, Chunmei ^a   Yang, Yongjie ^a   Hinton, Antentor ^a   Zhu, Liangru ^a,c   Shu, Gang ^a   Myers, Martin G ^d   Wu, Qi ^a   Tong, Qingchun ^e   Heisler, Lora K ^b   Xu, Yong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Binge eating; Dopamine; Lorcaserin; Neuron; Receptor; Serotonin

Indexed keywords

DEXFENFLURAMINE; DOPAMINE; FLUOXETINE; LORCASERIN; MESSENGER RNA; SEROTONIN 2C RECEPTOR; BENZAZEPINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINGE EATING DISORDER; BRAIN ELECTROPHYSIOLOGY; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HUNGER; INNERVATION; MALE; MESENCEPHALON; MOUSE; NEUROANATOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; ANIMAL; BULIMIA; C57BL MOUSE; DRUG EFFECTS; EATING; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; VENTRAL TEGMENTUM;

ANIMALS; BENZAZEPINES; BULIMIA; DOPAMINERGIC NEURONS; EATING; FEMALE; FLUOXETINE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN UPTAKE INHIBITORS; VENTRAL TEGMENTAL AREA;

EID: 84995646353     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.06.005     Document Type: Article

References (47)

1. 1 Mitchell, J.E., Mussell, M.P., Comorbidity and binge eating disorder. Addict Behav 20 (1995), 725–732.
2. 2 Patrick, L., Eating disorders: A review of the literature with emphasis on medical complications and clinical nutrition. Altern Med Rev 7 (2002), 184–202.
3. 3 Hudson, J.I., Hiripi, E., Pope, H.G. Jr., Kessler, R.C., The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 61 (2007), 348–358.
4. 4 Jimerson, D.C., Lesem, M.D., Kaye, W.H., Hegg, A.P., Brewerton, T.D., Eating disorders and depression: Is there a serotonin connection?. Biol Psychiatry 28 (1990), 443–454.
5. 5 Monteleone, P., Brambilla, F., Bortolotti, F., Maj, M., Serotonergic dysfunction across the eating disorders: Relationship to eating behaviour, purging behaviour, nutritional status and general psychopathology. Psychol Med 30 (2000), 1099–1110.
6. 6 Steiger, H., Eating disorders and the serotonin connection: State, trait and developmental effects. J Psychiatry Neurosci 29 (2004), 20–29.
7. 7 Kaye, W., Neurobiology of anorexia and bulimia nervosa. Physiol Behav 94 (2008), 121–135.
8. 8 Sabine, E.J., Yonace, A., Farrington, A.J., Barratt, K.H., Wakeling, A., Bulimia nervosa: A placebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol 15:suppl 2 (1983), 195S–202S.
9. 9 Pope, H.G. Jr., Hudson, J.I., Jonas, J.M., Yurgelun-Todd, D., Bulimia treated with imipramine: A placebo-controlled, double-blind study. Am J Psychiatry 140 (1983), 554–558.
10. 10 Mitchell, J.E., Groat, R., A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol 4 (1984), 186–193.
11. 11 Walsh, B.T., Stewart, J.W., Roose, S.P., Gladis, M., Glassman, A.H., Treatment of bulimia with phenelzine: A double-blind, placebo-controlled study. Arch Gen Psychiatry 41 (1984), 1105–1109.
12. 12 Hughes, P.L., Wells, L.A., Cunningham, C.J., Ilstrup, D.M., Treating bulimia with desipramine: A double-blind, placebo-controlled study. Arch Gen Psychiatry 43 (1986), 182–186.
13. 13 Barlow, J., Blouin, J., Blouin, A., Perez, E., Treatment of bulimia with desipramine: A double-blind crossover study. Can J Psychiatry 33 (1988), 129–133.
14. 14 Rowland, N.E., Carlton, J., Neurobiology of an anorectic drug: Fenfluramine. Prog Neurobiol 27 (1986), 13–62.
15. 15 Stunkard, A., Berkowitz, R., Tanrikut, C., Reiss, E., Young, L., d-Fenfluramine treatment of binge eating disorder. Am J Psychiatry 153 (1996), 1455–1459.
16. 16 Blouin, A.G., Blouin, J.H., Perez, E.L., Bushnik, T., Zuro, C., Mulder, E., Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol 8 (1988), 261–269.
17. 17 Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V., Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997), 581–588.
18. 18 van Gestel, M.A., Kostrzewa, E., Adan, R.A., Janhunen, S.K., Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans. Br J Pharmacol 171 (2014), 4767–4784.
19. 19 Bello, N.T., Hajnal, A., Dopamine and binge eating behaviors. Pharmacol Biochem Behav 97 (2010), 25–33.
20. 20 Rada, P., Avena, N.M., Hoebel, B.G., Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. Neuroscience 134 (2005), 737–744.
21. 21 Hajnal, A., Norgren, R., Repeated access to sucrose augments dopamine turnover in the nucleus accumbens. Neuroreport 13 (2002), 2213–2216.
22. 22 Kelley, A.E., Berridge, K.C., The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22 (2002), 3306–3311.
23. 23 Schultz, W., Getting formal with dopamine and reward. Neuron 36 (2002), 241–263.
24. 24 Halpern, C.H., Tekriwal, A., Santollo, J., Keating, J.G., Wolf, J.A., Daniels, D., Bale, T.L., Amelioration of binge eating by nucleus accumbens shell deep brain stimulation in mice involves D2 receptor modulation. J Neurosci 33 (2013), 7122–7129.
25. 25 Benoit-Marand, M., Borrelli, E., Gonon, F., Inhibition of dopamine release via presynaptic D2 receptors: Time course and functional characteristics in vivo. J Neurosci 21 (2001), 9134–9141.
26. 26 Corwin, R.L., Wojnicki, F.H., Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions. Behav Pharmacol 20 (2009), 537–548.
27. 27 Wong, K.J., Wojnicki, F.H., Corwin, R.L., Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions. Pharmacol Biochem Behav 92 (2009), 528–536.
28. 28 Beier, K.T., Steinberg, E.E., DeLoach, K.E., Xie, S., Miyamichi, K., Schwarz, L., et al. Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping. Cell 162 (2015), 622–634.
29. 29 Czyzyk, T.A., Sahr, A.E., Statnick, M.A., A model of binge-like eating behavior in mice that does not require food deprivation or stress. Obesity (Silver Spring) 18 (2010), 1710–1717.
30. 30 Yu, Z., Geary, N., Corwin, R.L., Ovarian hormones inhibit fat intake under binge-type conditions in ovariectomized rats. Physiol Behav 95 (2008), 501–507.
31. 31 Cao, X., Xu, P., Oyola, M.G., Xia, Y., Yan, X., Saito, K., et al. Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice. J Clin Invest 124 (2014), 4351–4362.
32. 32 Xu, Y., Berglund, E.D., Sohn, J.W., Holland, W.L., Chuang, J.C., Fukuda, M., et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci 13 (2010), 1457–1459.
33. 33 Xu, Y., Jones, J.E., Kohno, D., Williams, K.W., Lee, C.E., Choi, M.J., et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60 (2008), 582–589.
34. 34 Bubar, M.J., Cunningham, K.A., Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146 (2007), 286–297.
35. 35 Leinninger, G.M., Opland, D.M., Jo, Y.H., Faouzi, M., Christensen, L., Cappellucci, L.A., et al. Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance. Cell Metab 14 (2011), 313–323.
36. 36 Kiss, J., Leranth, C., Halasz, B., Serotoninergic endings on VIP-neurons in the suprachiasmatic nucleus and on ACTH-neurons in the arcuate nucleus of the rat hypothalamus: A combination of high resolution autoradiography and electron microscopic immunocytochemistry. Neurosci Lett 44 (1984), 119–124.
37. 37 Berglund, E.D., Liu, C., Sohn, J.W., Liu, T., Kim, M.H., Lee, C.E., et al. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest 123 (2013), 5061–5070.
38. 38 Thomsen, W.J., Grottick, A.J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325 (2008), 577–587.
39. 39 Van Bockstaele, E.J., Cestari, D.M., Pickel, V.M., Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: Potential sites for modulation of mesolimbic dopamine neurons. Brain Res 647 (1994), 307–322.
40. 40 Herve, D., Pickel, V.M., Joh, T.H., Beaudet, A., Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res 435 (1987), 71–83.
41. 41 Guan, X.M., McBride, W.J., Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 23 (1989), 541–547.
42. 42 Di Matteo, V., Di Giovanni, G., Di Mascio, M., Esposito, E., SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38 (1999), 1195–1205.
43. 43 Di Matteo, V., Pierucci, M., Esposito, E., Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 89 (2004), 418–429.
44. 44 Watabe-Uchida, M., Zhu, L., Ogawa, S.K., Vamanrao, A., Uchida, N., Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74 (2012), 858–873.
45. 45 Hewitt, K.N., Lee, M.D., Dourish, C.T., Clifton, P.G., Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71 (2002), 691–700.
46. 46 McGuirk, J., Goodall, E., Silverstone, T., Willner, P., Differential effects of d-fenfluramine, l-fenfluramine and d-amphetamine on the microstructure of human eating behaviour. Behav Pharmacol 2 (1991), 113–119.
47. 47 Nonogaki, K., Strack, A.M., Dallman, M.F., Tecott, L.H., Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4 (1998), 1152–1156.